| Identification | Back Directory | [Name]
LJ570 | [CAS]
2252488-69-8 | [Synonyms]
LJ570
1,1'-Biphenyl]-4-propanoic acid,α-([1,1'-biphenyl]-4-yloxy)-,(αS)-
[1,1'-Biphenyl]-4-propanoic acid, α-([1,1'-biphenyl]-4-yloxy)-, (αS)- | [Molecular Formula]
C27H22O3 | [MDL Number]
MFCD32062685 | [MOL File]
2252488-69-8.mol | [Molecular Weight]
394.47 |
| Chemical Properties | Back Directory | [Boiling point ]
601.0±55.0 °C(Predicted) | [density ]
1.185±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [pka]
2.96±0.10(Predicted) |
| Hazard Information | Back Directory | [Description]
LJ570 is the first PPARα/γ Dual Agonist Able To Bind to Canonical and Alternative Sites of PPARγ and To Inhibit Its Cdk5-Mediated Phosphorylation. LJ570 is a potent partial agonist of both PPARα and γ subtypes. LJ570 inhibited the Cdk5-mediated phosphorylation of PPARγ at serine 273 that is currently considered the mechanism by which some PPARγ partial agonists exert antidiabetic effects similar to thiazolidinediones, without showing their typical side effects. LJ570 may be useful for treatment of dyslipidemic type 2 diabetes. | [Uses]
LJ570 is a PPARα/PPARγ dual agonist with EC50s of 1.05 and 0.12 μM, respectively[1]. | [target]
LJ570 is the first PPARα/γ Dual Agonist Able To Bind to Canonical and Alternative Sites of PPARγ and To Inhibit Its Cdk5-Mediated Phosphorylation. | [IC 50]
PPARα: 1.05 μM (EC50); PPARγ: 0.12 μM (EC50) | [References]
[1] Laghezza A, et al. Identification of the First PPARα/γ Dual Agonist Able To Bind to Canonical and Alternative Sites of PPARγ and To Inhibit Its Cdk5-Mediated Phosphorylation. J Med Chem. 2018 Sep 27;61(18):8282-8298. DOI:10.1021/acs.jmedchem.8b00835 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|